GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jacobson Pharma Corp Ltd (HKSE:02633) » Definitions » Tax Expense

Jacobson Pharma (HKSE:02633) Tax Expense : HK$58 Mil (TTM As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jacobson Pharma Tax Expense?

Jacobson Pharma's tax expense for the months ended in Sep. 2024 was HK$35 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2024 was HK$58 Mil.


Jacobson Pharma Tax Expense Historical Data

The historical data trend for Jacobson Pharma's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobson Pharma Tax Expense Chart

Jacobson Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 46.03 34.26 43.73 42.98 44.41

Jacobson Pharma Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.84 19.13 21.58 22.84 35.09

Jacobson Pharma Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jacobson Pharma  (HKSE:02633) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Jacobson Pharma Tax Expense Related Terms

Thank you for viewing the detailed overview of Jacobson Pharma's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Jacobson Pharma Business Description

Traded in Other Exchanges
N/A
Address
388 Kwun Tong Road, Unit 2313-18, 23rd Floor, Tower 1, Millennium City 1, Kwun Tong, Kowloon, Hong Kong, HKG
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
Executives
Sum Kwong Yip, Derek 2305 Beneficiary of a trust
Lau Wing Hung
Kingshill Development Group Inc
Kingshill Development Limited
Ubs Trustees (b.v.i.) Limited
Queenshill Development Limited
Longjin Investments Limited
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si

Jacobson Pharma Headlines

No Headlines